Johnson & Johnson Cancer Trial Update Puts Erda-iDRS In Valuation Focus
unknown📝 Article Content
Johnson & Johnson (NYSE:JNJ) reported encouraging Phase 1 data for Erda-iDRS, an investigational drug-releasing system for certain non muscle invasive bladder cancers with FGFR alterations. The study met its primary safety goal and showed high rates of durable complete responses and recurrence free survival in intermediate and high risk patients. These results support ongoing Phase 2 and Phase 3 trials that are designed to further assess this localized, targeted approach. For investors...
📄 Summary
Johnson & Johnson (NYSE:JNJ) reported encouraging Phase 1 data for Erda-iDRS, an investigational drug-releasing system for certain non muscle invasive bladder cancers with FGFR alterations. The study met its primary safety goal and showed high rates of durable complete responses and recurrence free survival in intermediate and high risk patients. These results support ongoing Phase 2 and Phase 3 trials that are designed to further assess this localized, targeted approach. For investors...